Transcriptomics and Non-coding RNAs in Heart Failure

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 5331

Special Issue Editor


E-Mail Website
Guest Editor
1. Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain
2. Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Madrid, Spain
Interests: heart failure; acute cellular rejection; Golgi apparatus; cardiomyopathy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure is a shared chronic phase of cardiac functional impairment secondary to many etiologies and considered a serious global health challenge affecting at least 26 million people worldwide. Although many important advances in therapies and prevention have taken place during the last decade, mortality and morbidity are still high and the quality of life poor. Therefore, there is a need to develop new strategies for the management of this syndrome. In this sense, alterations in the gene expression of different pathways that can lead to heart failure are being studied. Gene expression requires precise regulation through selective and bidirectional transport between the nucleus and the cytoplasm, including membrane proteins, enzymes, ribosomal subunits, and different types of RNAs. Noncoding RNAs are emerging as potent and multifunctional regulators in all biological processes, and step by step, studies are unveiling associations between aberrant noncoding RNA expression and human diseases. Better known are miRNAs, where to date, emerging evidence has demonstrated that abnormal expression is associated with the pathological processes of cardiovascular diseases including heart failure, although their functional roles have not been completely understood. This can be contrasted to the lack of information around the expression of other sRNA as snoRNAs or scaRNAs, especially at the cardiac level.

Dr. Estefanía Tarazón
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gene expression
  • noncoding RNAs
  • transcriptomic
  • heart failure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 841 KiB  
Article
Implication of Sphingolipid Metabolism Gene Dysregulation and Cardiac Sphingosine-1-Phosphate Accumulation in Heart Failure
by Lorena Pérez-Carrillo, Isaac Giménez-Escamilla, Luis Martínez-Dolz, Ignacio José Sánchez-Lázaro, Manuel Portolés, Esther Roselló-Lletí and Estefanía Tarazón
Biomedicines 2022, 10(1), 135; https://doi.org/10.3390/biomedicines10010135 - 8 Jan 2022
Cited by 10 | Viewed by 2649
Abstract
Disturbances in sphingolipid metabolism lead to biological function dysregulation in many diseases, but it has not been described in heart failure (HF). Sphingosine-1-phosphate (S1P) levels have not ever been measured in the myocardium. Therefore, we analyze the gene dysregulation of human cardiac tissue [...] Read more.
Disturbances in sphingolipid metabolism lead to biological function dysregulation in many diseases, but it has not been described in heart failure (HF). Sphingosine-1-phosphate (S1P) levels have not ever been measured in the myocardium. Therefore, we analyze the gene dysregulation of human cardiac tissue by mRNA-seq (n = 36) and ncRNA-seq (n = 50). We observed most major changes in the expression of genes belonging to de novo and salvage pathways, and the tight gene regulation by their miRNAs is largely dysregulated in HF. We verified using ELISA (n = 41) that ceramide and S1P accumulate in HF cardiac tissue, with an increase in the ceramide/S1P ratio of 57% in HF. Additionally, changes in left ventricular mass and diameters are directly related to CERS1 expression and inversely related to S1P levels. Altogether, we define changes in the main components of the sphingolipid metabolism pathways in HF, mainly de novo and salvage, which lead to an increase in ceramide and S1P in cardiac tissue, as well as an increase in the ceramide/S1P ratio in HF patients. Therapeutic gene modulation focused on restoring ceramide levels or reversing the ceramide/S1P ratio could be a potential therapy to be explored for HF patients. Full article
(This article belongs to the Special Issue Transcriptomics and Non-coding RNAs in Heart Failure)
Show Figures

Graphical abstract

Review

Jump to: Research

14 pages, 1517 KiB  
Review
Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure
by Carlos Garcia-Padilla, Estefanía Lozano-Velasco, Virginio Garcia-Lopez, Amelia Aranega, Diego Franco, Virginio Garcia-Martinez and Carmen Lopez-Sanchez
Biomedicines 2022, 10(12), 3076; https://doi.org/10.3390/biomedicines10123076 - 30 Nov 2022
Cited by 5 | Viewed by 2137
Abstract
Heart failure constitutes a clinical complex syndrome with different symptomatic characteristics depending on age, sex, race and ethnicity, among others, which has become a major public health issue with an increasing prevalence. One of the most interesting tools seeking to improve prevention, diagnosis, [...] Read more.
Heart failure constitutes a clinical complex syndrome with different symptomatic characteristics depending on age, sex, race and ethnicity, among others, which has become a major public health issue with an increasing prevalence. One of the most interesting tools seeking to improve prevention, diagnosis, treatment and prognosis of this pathology has focused on finding new molecular biomarkers since heart failure relies on deficient cardiac homeostasis, which is regulated by a strict gene expression. Therefore, currently, analyses of non-coding RNA transcriptomics have been oriented towards human samples. The present review develops a comparative study emphasizing the relevance of microRNAs, long non-coding RNAs and circular RNAs as potential biomarkers in heart failure. Significantly, further studies in this field of research are fundamental to supporting their widespread clinical use. In this sense, the various methodologies used by the authors should be standardized, including larger cohorts, homogeneity of the samples and uniformity of the bioinformatic pipelines used to reach stratification and statistical significance of the results. These basic adjustments could provide promising steps to designing novel strategies for clinical management of patients with heart failure. Full article
(This article belongs to the Special Issue Transcriptomics and Non-coding RNAs in Heart Failure)
Show Figures

Figure 1

Back to TopTop